PTC Therapeutics PTCT Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Emflaza | $120.05M-18.0% | $146.36M-13.8% | $169.8M-9.0% | $186.58M-5.5% | $197.52M-4.7% | |
| Other Products | $37.42M+0.4% | $37.27M+7.8% | $34.56M-3.8% | $35.92M-8.6% | $39.29M+6.3% | |
| Translarna | -$125.81M-27.6% | -$98.63M— | —— | —— | —— | |
| Revenue by Geography | ||||||
| All Other Countries Other Than Russia Brazil And United States | $155.39M-7.7% | $168.41M+10.3% | $152.69M-7.9% | $165.78M-15.5% | $196.28M-0.6% | |
| BR | $97.37M+48.3% | $65.66M+3.5% | $63.46M-24.0% | $83.45M+14.5% | $72.88M+1.1% | |
| RU | $65.18M-35.1% | $100.45M-23.6% | $131.41M+22.5% | $107.26M+17.5% | $91.29M-13.4% | |
| US | $340.91M+35.2% | $252.18M+32.0% | $191.06M+2.4% | $186.58M-5.5% | $197.52M-4.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does PTC Therapeutics break its business down?
- PTC Therapeutics (PTCT) reports revenue by product across 6 parts — Emflaza, Other Products, Sephience, Translarna1 and Translarna. Each is extracted from the segment footnotes and tracked over time.
- Where does PTC Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in PTC Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
